Abstract
Background India started Covid-19 vaccination from January 16, 2021 after the approval of two candidate vaccines namely Covishield ™ and Covaxin ™. We report antibody responses among healthcare workers following two doses of Covishield ™ vaccination in a tertiary care setting.
Methods This prospective serosurveillance study was done among healthcare workers of Jubilee Mission Medical College, vaccinated during January- March 2021. Blood samples were drawn from 170 participants after their 1st dose and from 156 participants after their 2nd dose of Covishield ™ to measure the specific Ig G antibodies against the recombinant S1 subunit of the S protein of SARS-CoV-2.
Results The median level of anti SARS CoV-2 Ig G antibody 28 days after the first dose vaccination is 3.64 S/C (IQR=5.91) and 11.6 S/C (IQR= 5.97) after 14 days of second dose vaccination. Protective levels of anti SARS CoV-2 Ig G antibodies is developed by 25 participants (14.7%) after 28 days of first dose of vaccination and by 109 participants (69.9%) after 14 days of second dose. 18-44 years age group (p=0.027) and absence of comorbidities (p=0.079) are associated with protective IgG levels.
Conclusions Rise in specific Ig G is observed after vaccination. Higher antibody response is observed with younger age group and absence of comorbidities, though statistically not significant. The influence of BMI is also not significant.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
this study is an an observational study
Funding Statement
No external funding received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol has been approved by the Institutional Ethic Committee of Jubilee Mission Medical College & Research Institute, Thrissur (IEC study ref no: 38/21/IEC/JMMC & RI dated 18-02-2021).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding No external funding was received for this study.
Data Availability
data will be available on request
LIST OF ABBREVIATIONS
- SARS
- CoV-2 Severe Acute Respiratory Virus Coronavirus- type 2
- HCW
- Health Care Worker
- AEFI
- Adverse Events Following Immunization
- Ig G
- Immunoglobulin Gamma
